CanSino Biologics Reports H1 2023 Revenues Down 96.7% YOY, COVID-19 Demand Decreases
China-based CanSino Biologics (SHA: 688185, HKG: 6185) has released its financial report for the first...
Finanical Reports
Sandoz Reports H1 2023 Financials with 8% YOY Growth, Separation from Novartis Looms
Switzerland-based Sandoz (SWX: SDZ) has published its financial statements for the first half of 2023,...
Junshi Biosciences Reports H1 2023 Revenue Dip Amid Commercial Success and R&D Focus
China’s Junshi Biosciences (HKG: 1877; SHA: 688180) has released its financial report for the first...
Lee’s Pharmaceutical Holdings Ltd Reports H1 2023 Revenue Dip Amid Product Portfolio Growth
China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has released its financial report for the first...
Johnson & Johnson Reports H1 2023 Sales Growth Following Kenvue Spinoff
Global healthcare giant Johnson & Johnson (J&J; NYSE: JNJ) has released a financial update for...
Zhejiang Dian Diagnostics Reports 2023H1 Revenue Dip, Strategic Expansion Continues
China-based Zhejiang Dian Diagnostics Co., Ltd (SHE: 300244) has released its financial report for the...
Luye Pharma Group Reports H1 2023 Revenue Growth with Strong Oncology and CNS Sales
China-based Luye Pharma Group (HKG: 2186) has announced its financial performance for the first half...
Lundbeck A/S Reports 10% H1 2023 Revenue Increase with Record-Breaking Sales
Denmark-based biopharmaceutical company H. Lundbeck A/S (OTCMKTS: HLBBF) has released its financial report for the...
Harbour BioMed Reports First Profitable Half-Year in H1 2023 Financial Results
China-based Harbour BioMed (HKG: 2142) has released its interim financial report for the first half...
Luye Pharma Group’s Subsidiary Boan Biotechnology Reports 18.4% Revenue Growth in H1 2023
China-based Luye Pharma Group’s (HKG: 2186) controlling subsidiary, Shandong Boan Biotechnology Co., Ltd (HKG: 6955),...
3SBio Inc. Reports H1 2023 Revenue Growth and Expansion in Digital Marketing
China-based 3SBio Inc. (HKG: 1530) has released its financial report for the first half of...
Innovent Biologics Reports 20.6% YOY Revenue Growth in H1 2023 Financials
China-based Innovent Biologics Inc., (HKG: 1801) has released its financial results for the first half...
WuXi Biologics Reports 17.8% Revenue Growth and Expands Service Scope in H1 2023
China-based Contract Research, Development, and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) has released its...
Everest Medicines Reports Q1 2023 Revenue Growth and Pipeline Progress
China-based Everest Medicines (HKG: 1952) has announced its financial and corporate update for the first...
RemeGen Ltd Reports 20.56% YOY Revenue Growth in H1 2023 Financial Results
China-based RemeGen Ltd (SHA: 688331, HKG: 9995) has released its financial report for the first...
Ascentage Pharma’s 2023 Interim Report: 49% YOY Revenue Growth and Market Expansion
China-based Ascentage Pharma (HKG: 6855) has released its 2023 interim financial report, revealing a 49%...
Ascletis Pharma Inc. Reports 21.7% Revenue Increase in H1 2023, Led by Ritonavir Sales
China-based Ascletis Pharma Inc., (HKG: 1672) has revealed revenues of RMB 46.51 million (USD 6.38...
New Horizon Health Ltd Reports 264.6% YOY Revenue Increase and First Recurring Profits
China-based New Horizon Health Ltd (HKG: 6606), a leading cancer diagnostics developer, has released its...
Jiangsu Hengrui Pharmaceuticals Reports 9.19% YOY Revenue Growth in H1 2023 Financial Report
Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276) has released its financial report for the first...
JD Healthcare Reports 34% Revenue Growth and Triples Non-IFRS Profits in 2023 Interim Report
JD Healthcare, a subsidiary of China’s e-commerce giant JD.com (NASDAQ: JD), has released its 2023...